期刊文献+

益钙宁治疗骨质疏松症骨痛45例疗效观察 被引量:8

45 CASES OF PRIMARY OSTEOPOROSIS PATIENTS TREATED WITH ELCATONIN
原文传递
导出
摘要 益钙宁(人工合成鳗鱼降钙素,Elcatonin)治疗原发性骨质疏松症45例,有明显的减轻骨痛和改善活动功能的效果,有效率为91.1%,31例(占68.9%)病人停药后改善疼痛作用持续1个月以上。血TRAP和尿Ftyp排量在用约后均有明显降低,支持此药行抑制破骨细胞活性的作用。仅用药初期少数病人有轻微脸红、心悸或恶心等副作用。可自行缓解或对症处理后消失。 45 cases (female 43, male 2 ) of primary osteoporosis patients, average age 65.2±7.5 years, treated with Elcatonin by intramuscular injection 10 U each time, twice a week for four weeks. 63.9%- 80.0% of the patients had shown improvement in various symptoms of osteoporosis. Analgesic effect appeared 2 weeks later and became obvious after 3 weeks of treatment. This effect persisted for more than one month on 68.9% patients after withdrawal of Elcatonin. The mean values of serum TRAP and urinary hydroxyproline decreased significantly from 9.8 IU/ L to 8.4 IU / L (P< 0.01) and from 26.5 mg/24h to 19.7 mg/24h (P<0.01) respectively. The side effects were mild and negligible. The rate of effectiveness was 91.9%. Our conclusion is that Elcatonin is a safe and effective remedy for relief of bone pain and for suppressing the activity of osteoclasts in osteoporosis patients.
出处 《中华内分泌代谢杂志》 CAS CSCD 北大核心 1993年第3期155-157,共3页 Chinese Journal of Endocrinology and Metabolism
关键词 益钙宁 骨质松症 羟脯氨酸 疗效 Osteoporosis Elcatonin
  • 相关文献

同被引文献41

  • 1林守清.雌激素在绝经后骨质疏松症防治中的应用[J].实用妇产科杂志,1995,11(5):238-240. 被引量:4
  • 2朱建民,程秦娣.绝经后骨质疏松[J].中华内分泌代谢杂志,1996,12(4):234-238. 被引量:17
  • 3杨竹林.二磷酸盐类治疗骨质疏松的研究进展[J].现代诊断与治疗,1997,8(2):85-86. 被引量:1
  • 4迟志波 周体译.降钙素对人的近期和远期副作用及安全性的前瞻性研究[J].国外医学:内分泌学分册,1994,14(2):111-111.
  • 5裴剑浩 冯凭(译).二磷酸盐在骨质疏松中的应用前景[J].国外医学:内分泌学分册,1994,14(1):54-54.
  • 6迟志波 周仁(译).VitE能抗骨质疏松吗?[J].国外医学:内分泌学分册,1994,14(4):187-187.
  • 7Kanis JA, Johnell O, Black DM, et al. Effect of raloxirene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of multiple outcomes of raloxifene evaluation trial[ J ]. Bone, 2003, 33 : 293 - 300.
  • 8Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. Multiple outcomes of raloxifene evaluation (MORE)[J]. JAMA, 1999, 282:637-645.
  • 9Delmas PD, Ensrud KE, Adaehi JT, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial[ J ]. J Clin Endoerinol & Metab, 2002, 87:3609-3617.
  • 10Delmas PD, Genant HK, Crans GG, et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial[J]. Bone, 2003, 33:522 -532.

引证文献8

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部